Latest Regulatory Change News

Xenitra’s Hong Kong subsidiary Fukang has inked a three-year A$5 million procurement framework for specialised medical nutrition products, broadening its foothold beyond OTC medicines in China’s booming healthcare market.

Amplitude Energy (ASX:AEL) posted record production and earnings for FY26, underpinned by strong operational execution and progress on the East Coast Supply Project (ECSP). The company strengthened its balance sheet, reduced net debt by 85%, and targets first gas from ECSP in 2028.

Vita Life Sciences delivered a robust first half in 2026 with revenue up 6.1% to A$48.3 million and net profit after tax rising 14.9% to A$5.54 million. The company declared a higher interim dividend, reflecting improved margins and regional market momentum.

Scalare Partners offers 87 bonus options per 100 shares to eligible shareholders alongside piggyback options, aiming to mitigate dilution from upcoming convertible note conversions. Directors plan to exercise their options, with potential capital raised earmarked for working capital.

The a2 Milk Company posted a 12.4% rise in FY26 revenue to NZ$1.975 billion, but net profit from continuing operations fell 5.8% amid supply chain disruptions in China. The company declared a $300 million special dividend and expects mid single-digit revenue growth in FY27.

WAM Strategic Value delivered a solid 9.5% portfolio return for FY2026, outpacing the ASX All Ordinaries by 3.8%, while declaring a fully franked dividend of 6.5 cents per share. New capital gains tax rules are reshaping investor appetite, boosting demand for listed investment companies like WAM.

Resouro Strategic Metals has closed its $2.5 million private placement, issuing 10 million shares at 25 cents each to support the environmental program and feasibility study for its Tiros project in Brazil.

Contact Energy (ASX:CEN) posted a 62% jump in FY26 net profit to NZD 423 million, driven by its Manawa acquisition and a near 98% renewable generation mix, while committing to net zero emissions by 2035.

Kinatico Limited reports a robust FY26 with SaaS revenue growth driving total revenue up 9.4% to $35.2 million and net profit after tax soaring 78.5% to $2.0 million, underpinned by its AI-native compliance platform.

WAM Income Maximiser (ASX: WMX) has kicked off a $125.4 million entitlement offer priced at $1.62 per share, alongside a $47 million placement, aiming to bolster its capital base while maintaining a 7.1% fully franked dividend yield.

Aura Energy has locked in a commercially proven processing flowsheet for its Tiris Uranium Project and signed a non-binding MOU with a major nuclear utility, aiming for a binding agreement and Final Investment Decision by year-end 2026.

Tissue Repair advances its US Phase III chronic wound trial with 100 patients randomised and targets October FDA 510(k) submission. The company reports a robust cash position bolstered by R&D refunds and has cut manufacturing scale-up costs.